DKK1蛋白表达与肝内胆管细胞癌患者淋巴结侵犯及其预后的相关性研究

doi:10.11904/j.issn.1002-3070.2017.03.007

摘要/Abstract

摘要： 目的探讨DKK1蛋白表达与肝内胆管细胞癌患者淋巴结侵犯及其预后的相关性。方法选择2005年1月—2012年12月来我院行切除治疗肝内胆管癌患者78例,制作肝内胆管细胞癌组织及癌旁组织的组织芯片,并于术前进行生化指标测定。患者术后每隔3个月复查1次,并结合患者的临床资料和病历资料,采用Kaplan-Meier法进行无复发生存曲线及总生存曲线的绘制,采用Cox比例风险回归模型进行多因素分析,确定影响预后无复发生存时间(Relapse-free survival,RFS)和总生存时间(Overall survival,OS)的因素。结果 DKK1蛋白表达阴性与表达阳性的患者间GGT、肝门淋巴结侵犯、Child-Pugh分级、MMP9差异存在统计学意义(P＜0.05)。78例肝内胆管细胞癌患者组织芯片结果发现DKK1蛋白在肝内胆管细胞癌的阳性表达率为35.90%(28/78),在癌旁组织中的阳性表达率为14.10%(11/78)。78例肝内胆管细胞癌患者的1、3、5年的总生存率和无复发生存率分别为51.28%(40/78)与50.00%(38/78)、41.03%(32/78)与38.46%(30/78)、25.64%(20/78)与23.08%(18/78)。相关危险性因素经单因素、多因素分析后,研究结果显示GGT、CA19-9、CEA、肿瘤大小、DKK1、肝门淋巴结侵犯是影响肝内胆管细胞癌患者RFS的预后因素;CEA、肿瘤大小、DKK1、肝门淋巴结侵犯是影响肝内胆管细胞癌患者DFS的预后因素。DKK1蛋白表达阳性与阴性的OS与RFS曲线显示,5年后肝内胆管细胞癌患者DKK1蛋白表达阳性与阴性的总生存率分别为28.20%与20.51%;无复发生存率分别为24.36%与21.79%。结论肝内胆管细胞癌患者淋巴结侵犯与否与DKK1蛋白表达密切相关,DKK1蛋白表达可能是影响肝内胆管细胞癌患者OS和RFS的预后因素。

关键词: DKK1蛋白, 肝内胆管细胞癌, 淋巴结侵犯, 预后

Abstract: Objective The objectives of this study were to investigate the relationship between DKK1 protein expression and lymph node invasion,and prognosis in patients with intrahepatic cholangiocarcinoma.Methods From January 2005 to December 2012,78 patients with intrahepatic cholangiocarcinoma were treated with endoscopic resection.Tissue microarray of intrahepatic cholangiocarcinoma and adjacent tissues were done and biochemical indexes were measured before operation.The patients were recruited every 3 months after operation.The Kaplan-Meier method was used to analyze the recurrence-free survival curve and the overall survival curve.The Cox proportional hazards regression model was used to analyze the multivariate analysis and to determine the factors that affect the disease-free survival(RFS)and overall survival(OS).Results There were significant differences in the expression of GGT,hepatic portal lymph node invasion,Child-Pugh grade,MMP9 and DKK1 protein in the negative and positive expression of intrahepatic cholangiocarcinoma(P＜0.05).The positive expression rate of DKK1 protein in intrahepatic cholangiocarcinoma was 35.90%(28/78),and the positive expression rate of DKK1 protein in hilar cholangiocarcinoma was 14.10%(11/78).RFS and OS in 78 cases of intrahepatic cholangiocarcinoma were 51.28%(40/78)and 50.00%(38/78),41.03%(32/78)and 38.46%(30/78),25.64%(20/78)and 23.08%(18/78)after surgery for 1,3 and 5 years,respectively.The results from univariate and multivariate analysis showed that GGT,CA19-9,CEA,tumor size,DKK1 and hilar lymph node invasion were the prognostic factors of OS in patients with intrahepatic cholangiocarcinoma.CEA,tumor size,DKK1 and hilar lymph node involvement were prognostic factors for RFS in patients with intrahepatic cholangiocarcinoma.DKK1 protein expression positive and negative OS curve or RFS curve showed that 5 years after intrahepatic cholangiocarcinoma patients DKK1 protein expression positive and negative OS were 28.20% and 20.51%;RFS were 24.36% and 21.79%.Conclusion The expression of DKK1 protein is closely related to lymph node invasion in patients with intrahepatic cholangiocarcinoma.The expression of DKK1 protein is the prognostic factor of OS and RFS in patients with intrahepatic cholangiocarcinoma.

Key words: DKK1 protein, Intrahepatic cholangiocarcinoma, Lymph node invasion, Prognosis

中图分类号:

R735.7

赵利锋，程伟华，雷达，杨彦伟，王钢. DKK1蛋白表达与肝内胆管细胞癌患者淋巴结侵犯及其预后的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(3): 228-233.

ZHAO Lifeng,CHENG Weihua,LEI Da,YANG Yanwei,WANG Gang. The relationship between DKK1 protein expression and lymph node invasion,and prognosis in patients with intrahepatic cholangiocarcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 228-233.

参考文献

1 Bartsch F,Baumgart J,Heinrich S,et al.Resection of intrahepatic cholangiocarcinoma[J].HPB,2016,18(1):463-471.
2 李永胜,孙保君.肝内胆管癌手术治疗的预后影响因素分析[J].实用癌症杂志,2016,31(4):610-612.
3 陆凯,张博,董立巍,等.中下段胆管癌的预后影响因素分析[J].现代生物医学进展,2012,12(26):5068-5071.
4 王捷.对“1370例肝内胆管细胞癌肝切除术的疗效及预后因素分析”和“肝门部胆管癌手术切除的远期疗效及预后因素分析”的点评[J].中华消化外科杂志,2016,4(1):334.
5 Tian E,Zhan F,Walker R,et al.The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma[J].N Engl J Med,2003,349(26):2483-2494.
6 Wang JY,Zhou PR,Liu Y,et al.The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women[J].Pharmacogenomics,2016,17(3):209-217.
7 Ruo YS,Xin RY,Qiu JS,et al.High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery[J].Cancer,2013,119(5):993-1003.
8 董辉,丛文铭.提高肝癌规范化病理诊断水平,为临床精细化治疗保驾护航-《原发性肝癌规范化病理诊断指南(2015年版)》解读[J].中国普通外科杂志,2016,25(7):939-943.
9 李玉博,高雪梅,程敬亮,等.体素内不相干运动扩散加权成像在肝细胞癌术前分级中的应用[J].中国医学影像技术,2014,34(11):1669-1673.
10 权继传,解亦斌,田艳涛.国际抗癌联盟胃癌TNM分期系统第七版解读[J].中华诊断学电子杂志,2014,2(1):59-61.
11 余杏娟,许静,郑利民.组织芯片制备及在肝癌研究中的应用体会[J].中国免疫学杂志,2013,29(10):1089-1092.
12 Nagata S,Tomoeda M,Kubo C,et al.Intraductal polypoid growth variant of pancreatic acinar cell carcinoma metastasizing to the intrahepatic bile duct 6 years after surgery:A case report and literature review[J].Pancreatology,2012,12(1):23-26.
13 张登才,刘斌,张丽华,等.一种简便实用的组织芯片制作方法[J].诊断病理学杂志,2013,20(11):722-724.
14 Kononen J,Bubendorf L,Kallioniemi A,et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens[J].Nat Med,1998,4(4):844-847.
15 Yamabuki T,Takano AS,Ishikawa N,et al.Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas[J].Cancer Research,2007,67(6):2517-2525.
16 Forget MA,Turcotte S,Beauseigle D,et al.The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types[J].Br J Cancer,2007,96(4):646-653.
17 Sheng SL,Huang GB.Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer[J].Clinical Chemistry,2009,55(9):1656-1664.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[3]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[4]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[5]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[6]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[7]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[8]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[9]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[10]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[11]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[12]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[13]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.
[14]	李美艳, 陈永学, 侯俊德. Leptin、VEGF及不同麻醉方式对子宫内膜癌患者预后生存的影响[J]. 实用肿瘤学杂志, 2018, 32(5): 426-431.
[15]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.